Dr. Chandra Belani on Atezolizumab in NSCLC

Chandra P. Belani, MD
Published: Wednesday, Mar 16, 2016



Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

The immunotherapy agent has been studied in both the BIRCH and POPLAR trials. In the BIRCH study, atezolizumab met its primary endpoint, demonstrating a 27% objective response rate in patients whose disease had progressed on prior medicines and also expressed the highest levels of PD-L1.

In the POPLAR study, atezolizumab showed a statistically significant survival benefit compared to docetaxel in recurrent NSCLC patients who had had failed prior chemotherapy. There was an approximant 3-month difference in overall survival with atezolizumab compared to docetaxel.

PD-L1 seems to be a predictor of response and activity in NSCLC for atezolizumab, says Belani.



Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

The immunotherapy agent has been studied in both the BIRCH and POPLAR trials. In the BIRCH study, atezolizumab met its primary endpoint, demonstrating a 27% objective response rate in patients whose disease had progressed on prior medicines and also expressed the highest levels of PD-L1.

In the POPLAR study, atezolizumab showed a statistically significant survival benefit compared to docetaxel in recurrent NSCLC patients who had had failed prior chemotherapy. There was an approximant 3-month difference in overall survival with atezolizumab compared to docetaxel.

PD-L1 seems to be a predictor of response and activity in NSCLC for atezolizumab, says Belani.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x